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Summary    
The U.N. Guiding Principles on Business and Human Rights is the final 
work of the meticulous mandate upheld by the Special Representative of the 
Secretary-General between 2005 and 2011. It consists of three pillars, 
namely, the state duty to protect against human rights abuses by third 
parties, including business, the corporate responsibility to respect human 
rights, and access by victims to effective remedy. The focus of this thesis is 
on the second pillar, specifically the corporate responsibility of patent-
holding pharmaceutical companies to respect the right to health in access to 
medicines context. 
The research question that this thesis seeks to answer is what meaning the 
corporate responsibility to respect human rights as framed by the U.N. 
Guiding Principles signifies for patent-holding pharmaceutical companies in 
the access to medicines context, more specifically, whether it is 
comprehensive enough to meet the right to health requirements or not. The 
thesis initially establishes that the term ‘respect’ is meant to correlate with 
its meaning in human right law, which refers to non-infringement or ‘doing 
no harm’. Subsequently, the thesis avails itself of the right to health 
framework as a reference point to indicate the adverse human rights impacts 
of patent-holding pharmaceutical companies. As a response to these adverse 
impacts, specific corporate actions that should be taken are suggested, which 
often require initiative from companies such as price reductions in life-
saving medicines through participation in multi-stakeholder initiatives or 
engaging in voluntary licensing agreements. Justifications to support the 
aforementioned actions are also provided to make clear that the scope of 
corporate responsibility to respect in fact allows for broader interpretation of 
‘respect’ in certain circumstances.  
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1 Introduction 
1.1 Background 
 
Access to medicines has been at the centre of global health policy debates 
since the HIV/AIDS epidemic hit the world in the 1980s. Although the 
efforts in access to AIDS/HIV medicines have been successful thus far, 
there is still many challenges that lie ahead. According to the UNAIDS 
Global Report1, 9.7 million people who receive treatment represents only 
34% of the 28.6 million people eligible in 2013. It must be clarified that the 
access problem cannot be associated with only one type of disease. The 
challenges of a changing world have placed other diseases such as malaria, 
drug-resistant tuberculosis, hepatitis C or non-communicable diseases such 
as cancer or diabetes on the global health policy debates as well.  
Access to medicines is a multifaceted problem, which is caused by various 
actors due to various factors. Indeed, the Working Group on Access to 
Essential Medicines of the United Nations Millennium Project identified six 
barriers to access to medicines: 
Inadequate national commitment, inadequate human resources, failure of the 
international community to keep its promises of assistance to developing 
countries, lack of coordination of international aid, obstacles created by the 
Agreement on Trade Related Aspects of Intellectual Property Rights 
(TRIPS)2 and the current incentive structure for research and development 
of medicines and vaccines to address priority health needs of developing 
countries.3 This list clearly indicates that the problems posed by access to 
medicines are more complex and broader than a claim against the negative 
                                                 
1 UNAIDS, ‘Global Report: UNAIDS report on the global AIDS epidemic 2013’ 
(November 2013) p.46 
2 Agreement on Trade-Related Aspects of Intellectual Property Rights (15 April 1994) 
Marrakesh Agreement Establishing the World Trade Organization Annex 1C 1869 
U.N.T.S.299   
3 Stephen P. Marks, ‘Access to Essential Medicines as a Component of the Right to Health’ 
p.82 in: Andrew Clapham et al.(eds) Realizing the Right to Health Swiss Human Rights 
Book Vol.3 (rüffer & rub 2009) 
 
 5
impact of pharmaceutical patent rights.4 However, the thesis will focus itself 
on patent-related barriers, specifically the adverse impacts of patent-holding 
pharmaceutical companies5 on the right to health. 
Access to medicines is a field in which adverse human rights impacts of 
business enterprises are felt blatantly. Rapid expansion of the private sector 
and transnational economic activities6 have found its repercussions in this 
context as well. The most significant manifestation of the U.N. initiative in 
the human rights and business sphere would be the six year mandate of the 
Special Representative of the Secretary-General (SRSG), which was 
concluded in June 2011. Within the mandate, the ‘Protect Respect Remedy’ 
Framework7 (Framework) and the U.N. Guiding Principles on Business and 
Human Rights8 (U.N. Guiding Principles) have shined out and acquired 
unprecedented level of recognition from a wide range of stakeholders. 
While the Framework shows what should be done in the case of a business 
related human rights abuse, the Guiding Principles show how to do it.9 They 
are based upon three pillars, namely, the state duty to protect against human 
rights abuses by third parties, including business, the corporate 
responsibility to respect human rights, and access by victims to effective 
remedy. The focus of this thesis is on the second pillar, specifically the 
responsibility of patent-holding pharmaceutical companies to respect right 
to health in the access to medicines context. 
 
                                                 
4 Ibid. p.86 
5 The terms of company, corporation, business entity or enterprise are used interchangeably 
throughout the thesis.  
6 The SRSG, ‘Guiding Principles on Business and Human Rights: Implementing the United 
Nations “Protect, Respect and Remedy” Framework – Report of the Special Representative 
of the Secretary-General on the Issue of Human Rights and Transnational Corporations and 
Other Business Enterprises’ (21 March 2011) 17th Session Agenda Item 3 UN Doc 
A/HRC/17/31 p.3 
7 The SRSG, ‘Protect, Respect and Remedy: a Framework for Business and Human Rights 
- Report of the Special Representative of the Secretary-General on the Issue of Human 
Rights and Transnational Corporations and Other Business Enterprises’ (7 April 2008) 8th 
Session Agenda Item 3 UN Doc A/HRC/8/5  
8 supra note 6 
9 John G. Ruggie, Just Business: Multinational Corporations and Human Rights 
(W.W.Norton & Company 2013) p.81 
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1.2 Research Question 
 
The research question that this thesis seeks to answer is what meaning the 
corporate responsibility to respect - as framed in the Pillar II of the U.N. 
Guiding Principles - signifies for patent-holding pharmaceutical companies 
in the access to medicines context, more specifically, whether an 
expectation to ‘respect’ human rights is comprehensive enough to meet the 
right to health requirements or not. 
The SRSG was inspired by the international human rights law classification 
of respect, protect and fulfil when formulating the Framework.10 He makes 
clear distinction between what is required under the corporate responsibility 
to respect and what is desirable but not imperative. This thesis critically 
analyses and challenges this distinction. It challenges it by way of 
presenting the case of price reductions in life-saving medicines where the 
positive act - initiative - from the company is needed to make progress in 
the access problem and therefore, claims that the scope of corporate 
responsibility to respect needs to be interpreted broadly and the U.N. 
Guiding Principles in fact allows for this expansion.  
1.3 Structure & Method 
 
Access to medicines is a multifaceted problem in which different disciplines 
play a role. It requires an interdisciplinary approach, which accommodates 
different fields from human rights, intellectual property or international 
trade law, to non-legal areas such as voluntary corporate social 
responsibility schemes. Trilateral cooperation between World Trade 
Organization (WTO), World Intellectual Property Organization (WIPO) and 
World Health Organization (WHO) to promote the access to medicines is 
the proof of this multifaceted nature.11 Therefore, an interdisciplinary 
approach is covered throughout this thesis.  
                                                 
10 Ibid. 
11 WHO, WIPO and WTO, ‘Promoting Access to Medical Technologies and Innovation: 
Intersections Between Public Health, Intellectual Property and Trade’ (2012) available at 
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Chapter II starts with how different disciplines, i.e. intellectual property and 
human rights law approach the access problem whereby a systematic 
reflection on both disciplines is conducted. At the end, the chapter 
highlights the state-centric governance focus of both regimes as a 
shortcoming in international law. The methodology followed in this chapter 
is mainly a text analysis of primary sources in the two fields. Under the 
intellectual property heading, the focus is the post-TRIPS period because the 
TRIPS Agreement is the turning point, which significantly exacerbated the 
size of the access problem. Therefore, the TRIPS Agreement itself, the 
WTO mandated Doha Declaration of 200112 and the Decision of 30 August 
200313 constitute the primary area of focus. Under the human rights context, 
the focus is limited to the right to health. International Covenant on 
Economic, Social and Cultural Rights (ICESCR) and general comment 
No.14 of the Committee on Economic, Social and Cultural Rights (CESCR 
or Committee), which clarifies the normative content of the right to health 
and reports of the Special Rapporteur on the right to health (Special 
Rapporteur), are the main reference points.    
Chapter III introduces the reader to corporate responsibility to respect as 
framed in the U.N. Guiding Principles, specifically the human rights due 
diligence concept, which is the inherent tool for implementation of the 
corporate responsibility to respect. For operationalising the corporate 
responsibility in the patent-holding pharmaceutical industry, the chapter 
avails itself of the right to health framework as developed in international 
human rights law. This framework helps to identify more precisely the 
concrete adverse impacts of patent-holding pharmaceutical companies from 
access to medicines point of view. It must be clarified that this framework is 
formulated in relation to state obligations. However, this thesis uses it as a 
                                                                                                                            
<http://www.wto.org/english/res_e/booksp_e/pamtiwhowipowtoweb13_e.pdf> accessed on 
23 May 2014 
12 WTO, ‘Ministerial Declaration on the TRIPS Agreement and Public Health’ (14 
November 2001) WT/MIN(01)/DEC//2 
13 WTO, ‘Implementation of Paragraph 6 of the Doha Declaration on the TRIPS Agreement 
and Public Health’ (30 August 2003) WT/L/540 
 8
reference point in order to indicate the adverse impacts of patent-holding 
pharmaceutical companies.14 
Subsequently, chapter IV questions the boundaries of responsibility to 
respect and whether what is required of companies can be expanded or not. 
For this purpose, the example of price reductions in life-saving medicines 
through participation in multi-stakeholder initiatives and engaging in 
voluntary licensing agreements is chosen. At the end, the chapter brings 
justifications that the corporate responsibility to respect needs to be 
interpreted broadly for the given examples. It refers to the Guiding Principle 
19, which provides the appropriate actions expected from companies and 
several other arguments to support this main point. 
Chapter V completes the thesis by summing up the findings from the 
previous chapters. It also makes clear that the critical approach adopted in 
this thesis should not ignore the positive aspects of the U.N. Guiding 
Principles. 
1.4 Delimitations 
 
Access to medicines is related to various human rights such as the right to 
life, right not to be tortured, right to non-discrimination, right to an adequate 
standard of living or the right to enjoy the benefits of scientific progress and 
its applications. However, this thesis will limit itself within the scope of 
right to health. 
It must be highlighted that the focus of this thesis is access to essential 
medicines. Essential medicines are those that satisfy the priority health-care 
needs of the population. They are selected with due regard to disease 
prevalence, evidence on efficacy, safety and comparative cost-
effectiveness.15 Each country is expected to formulate its own national list 
of essential medicines according to its health-care priorities. The WHO 
                                                 
14 Joo-Young Lee and Paul Hunt, ‘Human Rights Responsibilities of Pharmaceutical 
Companies in Relation to Access to Medicines’ (2012) Journal of Law, Medicine & Ethics 
p.225 
15 Hans V. Hogerzeil, ‘Essential Medicines and Human Rights: What can they learn from 
each other?’ (2006) 84(5) Bulletin of the World Health Organization p.371 
 9
Model List of Essential Medicines16, which is updated every two years, 
serves as a comprehensive guide for the development of such lists.  
The focus of the international arena has mostly been on infectious diseases 
such as AIDS/HIV or malaria, which mainly affect the developing world. 
However, non-communicable diseases such as cancer, diabetes or 
cardiovascular diseases also pose a major threat to the developing world, 
hence, reflected in the WHO Model List of Essential Medicines. Therefore, 
this thesis does not limit its scope to a particular disease. 
Pharmaceutical patents have negative implications on both the innovation 
and distribution - dispensation - phases of medicines. This thesis uses the 
access terminology in the broad sense to cover both stages.  
Lastly, the responsibility of generic pharmaceutical companies is outside the 
scope of this thesis. The focus of this thesis is the multinational 
pharmaceutical companies, which significantly hinder the right to health 
through their patent rights. However, the internal structure of the company 
such as parent – affiliate company relationships are not considered in this 
thesis.  
 
 
                                                 
16 WHO Model List of Essential Medicines: 18th List (April 2013) available 
at<http://www.who.int/medicines/publications/essentialmedicines/en/index.html> accessed 
on 26 May 2014 
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2 Background of the access 
problem 
2.1 Introduction 
 
In Andrew Clapham’s words, “perhaps the most obvious threat to human 
rights has come from the inability of people to achieve access to expensive 
medicine, particularly in the context of HIV and AIDS”.17  
Access is defined as “having essential medicines continuously available and 
affordable at public or private health facilities or retail pharmacies that are 
within one hour’s walk from the homes of the population”.18 It is based 
upon the idea that “medicines are not simply commercial commodities, but 
basic human needs, fundamental human rights entitlements, and critical 
components of health care systems”.19 
This chapter will have a systematic reflection on both intellectual property, 
specifically post-TRIPS period and human rights law to present the 
background of the access problem. The relevance of these different regimes 
to the access discussion, the way they respond to it, divergences and 
alignments in their responses will be examined. To achieve this aim, the 
analysis will begin with the examination of the international legal 
framework surrounding the access problem. Afterwards, it will be presented 
that those legal efforts cluster around the state-centric governance 
mechanisms and that there is not a space for the non-state actors. 
                                                 
17 Andrew Clapham, Human Rights Obligations of Non-State Actors (Oxford University 
Press 2006) p.175 
18 United Nations Development Group, ‘Indicators for Monitoring the Millennium 
Development Goals’ (2003) p.89 available at 
<http://mdgs.un.org/unsd/mdg/Resources/Attach/Indicators/HandbookEnglish.pdf> 
accessed on 26 May 2014 
19 Lisa Forman, ‘Trade Rules, Intellectual Property, and the Right to Health’ (2007) 21 (3) 
Ethics & International Affairs (Wiley-Blackwell) p.337 
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2.2 International Legal Framework 
2.2.1 Trade Related Intellectual Property Law 
People have always been deprived of medicines around the world due to 
several reasons. However, patent related problems have been exacerbated 
particularly when the TRIPS was adopted in Morocco as an Annex IC to the 
Marrakesh Agreement Establishing the World Trade Organization20 on 15 
April 1994.  
TRIPS Agreement itself constitutes a big portion of the problem. Its ‘one 
size fits all’ or in Peter Yu’s words ‘super size fits all’21 approach ignores 
the fact that an optimal intellectual property system is bound to vary widely 
from one developing country to another. Each country has different 
scientific and technological structures.22 
The forum, which is responsible for intellectual property, has been the 
WIPO since 1967 and relevant treaties were the WIPO administrated Paris 
Convention for the Protection of Industrial Property23 and the Berne 
Convention for the Protection of Literary and Artistic Works.24 However, as 
global trade started to flourish in the early 1980s, inconsistent levels of 
patent protection in different markets started becoming very problematic for 
the developed world industry.25 Thus, the United States (U.S.) and other 
industrialised countries introduced intellectual property issues into the trade 
negotiations underway in the General Agreement on Tariffs and Trade 
                                                 
20 Marrakesh AgreementEstablishing the World Trade Organization (15 April 1994) 1867 
U.N.T.S. 154 
21 Peter K. Yu, ‘The Objectives and Principles of the TRIPS Agreement’ (2009) 46 (4) 
Houston Law Review p.981 
22 Graham Dutfield, ‘TRIPS and its impact on developing countries’ available at 
<http://www.scidev.net/global/policy-brief/trips-and-its-impact-on-developing-
countries.html> accessed on 24 May 2014  
23 Paris Convention for the Protection of Industrial Property (20 March 1883) as last revised 
in Stockholm on 14 July 1967 and amended in 1979 
24 Berne Convention for the Protection of Literary and Artistic Works (9 September 1886) 
as revised in Paris on 24 July 1971 and amended in 1979 
25 Laurence R. Helfer and Graeme W. Austin, Human Rights and Intellectual Property: 
Mapping the Global Interface (Cambridge University Press 2012) p.26 This thesis uses 
World Bank terminology when it refers to the developed, developing or least-developed 
country categories. 
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(GATT).26 The purpose was to shift the forum from WIPO, which mainly 
serves the interests of developing countries to GATT/WTO.27 In doing so, 
they managed to get their claims accepted in the TRIPS Agreement.  
TRIPS brings 1) a code of minimum intellectual property standards which 
obliges every country to have patent protection over pharmaceutical 
products 2) an enforcement mechanism, meaning that countries must not 
only enact legislation to be in compliance with TRIPS, but must implement 
domestic enforcement mechanisms as well to ensure that intellectual 
property rights are upheld28 3) a dispute settlement mechanism.29 WTO 
Dispute Settlement Body has the competence to deal with pharmaceutical 
patents and access related disputes because TRIPS is a WTO agreement. 
“Before TRIPS, pharmaceutical patent policies and practices were diverse. 
For example, many countries did not consider patents on such products as 
medicines and food to be in the public interest”.30 However, TRIPS 
Agreement started obliging every WTO-member state to provide patent 
protection of at least twenty years for pharmaceutical products. Therefore, 
after TRIPS, the extent of the problem has increased dramatically. No 
wonder why Jacques Gorlin, a key actor in the business network, said, “we 
got 95% of what we wanted”.31  
At the same time, TRIPS Agreement also brings certain safeguards such as 
Articles 7 and 8, which less developed countries attained as a result of hard-
earned bargaining during the TRIPS negotiations.32 Article 7 provides the 
objective as follows: 
The protection and enforcement of intellectual property rights should 
contribute to the promotion of technological innovation and to the transfer of 
                                                 
26 General Agreement on Tariffs and Trade 1994 (15 April 1994) Marrakesh Agreement 
Establishing the World Trade Organization Annex 1A 1867 U.N.T.S.187; see also ibid. 
p.27 
27 supra note 25 p.26-27 
28 Ibid. p.28 
29 Susan K. Sell and Aseem Prakash, ‘Using Ideas Strategically: The Contest Between 
Business and NGO Networks in Intellectual Property Rights’ (2004) 48 International 
Studies Quarterly p.159  
30 Ellen ‘t Hoen et al., ‘Driving a Decade of Change : HIV/AIDS, patents and access to 
medicines for all’ (2011) 14 (1) Journal of the International AIDS Society p.2 
31 supra note 29 p.160 
32 supra note 21 
 13
dissemination of technology, to the mutual advantage of producers and user 
of technological knowledge and in a manner conducive to social and 
economic welfare, and to a balance of rights and obligations.33  
Article 8 provides the interpretative principle of TRIPS Agreement34: 
     (1) Members may, in formulating or amending their laws and regulations, 
adopt measures necessary to protect public health and nutrition, and to 
promote the public interest in sectors of vital importance to their socio-
economic and technological development, provided that such measures are 
consistent with the provisions of this Agreement. 
     (2) Appropriate measures, provided that they are consistent with the 
provisions of this Agreement, may be needed to prevent the abuse of 
intellectual property rights by right holders or the resort to practices which 
unreasonably restrain trade or adversely affect the international transfer of 
technology.35 
These two provisions play an important role in interpreting and 
implementing the TRIPS Agreement36 despite certain shortcomings.37 As 
the WTO panel stated in the case of Canada-Patent Protection of 
Pharmaceutical Products, “both the goals and the limitations stated in 
Articles 7 and 8.1 must obviously be borne in mind when [examining the 
words of the limiting conditions in Article 30]38 as well as those of other 
provisions of the TRIPS Agreement which indicate its object and 
purposes”.39 Reichmann explains the power of these two provisions by 
stating that the safeguard provisions in Articles 7 and 8 may “legitimize ad 
                                                 
33 TRIPS Agreement Art.7 
34 supra note 21 p.1008 
35 TRIPS Agreement Art.8 
36 supra note 21 p.1046 
37 Ibid. p.1014 For example, Article 7 is a ‘should’, Article 8 is a ‘may’ provision and 
Article 8 is heavily constrained with the TRIPS-consistency requirement. 
38 TRIPS Agreement Article 30 brings limited exception possibility when its three-step test 
requirements are met.  
39 WTO, ‘Canada: Patent Protection of Pharmaceutical Products Panel Report’ (2000) 
WT/DS114/R para.7.26 
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hoc exceptions and limitations required by overriding national development 
needs or for reasons of national health, welfare and security”.40  
The WTO also adopted the Declaration on the TRIPS Agreement and Public 
Health (Doha Declaration) on 14 November 2001, which strongly reinforces 
the objectives and principles, set forth in Articles 7 and 8 of the TRIPS 
Agreement41. It emphasised that the “TRIPS Agreement can and should be 
interpreted and implemented in a manner supportive of WTO members’ 
right to protect public health and, in particular, to promote access to 
medicines for all”.42 In this connection, member states should be allowed to 
use the flexibilities brought forth by the TRIPS Agreement such as 
compulsory licensing option as demonstrated by Article 31. A government 
can allow someone else to produce the patented product or process without 
the consent of the patent-owner.43 This flexibility is referred to as 
‘compulsory licensing’. Each country itself determines the grounds for 
issuing a compulsory licensing. Furthermore, the WTO General Council 
also adopted the Decision of 30 August 2003 to clarify the situation for 
countries, which lack the necessary manufacturing capacity to benefit from 
compulsory licensing. This decision, after prolonged negotiations, allows 
the export of those generic products produced under compulsory licensing 
to a country with insufficient manufacturing capacity.44 This is referred to as 
the ‘parallel import’ possibility. These two WTO initiatives are very 
important demonstrating WTO’s affirmative attitude towards the application 
of Articles 7 and 8 of the TRIPS Agreement. 
The case of Natco v. Bayer45 from India is an example of how the national 
authorities can make use of those safeguards. The pharmaceutical company 
Bayer owns a patent on the drug named Nexavar, which treats liver and 
                                                 
40 supra note 21 p.1028; see also J.H Reichman, ‘From Free Riders to Fair Followers: 
Global Competition Under the TRIPS Agreement’ (1997) 29 (11) New York University 
Journal of International Law and Politics p.35 
41 supra note 21 p.995 
42 supra note 12 para.4 
43 For the definition 
<http://www.wto.org/english/tratop_e/trips_e/public_health_faq_e.htm> accessed on 24 
April 2014 
44 supra note 13  
45For the case <http://www.ipindia.nic.in/iponew/compulsory_license_12032012.pdf> 
accessed on 23 May 2014 
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kidney cancer. However, Natco, the Indian generic drug manufacturer, 
applied for a compulsory licensing on the ground that the price of the drug 
was too high and in conflict with the Section 84(1)(b) of the Indian Patent 
Act of 2005. The Controller of Patents highlighted that the compulsory 
licensing of the drug will enable Indians suffering from kidney and liver 
cancer to have greater access to the drug at stake and hence issued 
compulsory licensing. 
2.2.2 Human Rights Law 
There does not exist a human right to access to medicines, which is 
recognised by any international instrument. However, “it is an integral 
component of the right to health”46 both as treatment for epidemic and 
endemic diseases and as part of medical attention in the event of any kind of 
sickness.47 Several human rights bodies repeatedly asserted that the right to 
health encompasses a right of access to life-saving medicines.48  
The WHO Constitution defined health as “a state of complete physical, 
mental and social well-being and not merely the absence of disease or 
infirmity” as early as 1946.49 From that time, various international, regional 
and national human rights instruments recognised the right to health.50 
WHO Alma Ata Declaration of 197851 is historically very important in the 
access to medicines. It strongly emphasized that primary health care must be 
made accessible to individuals and families at a cost that the community and 
country can afford to maintain their self-reliance and self-determination. In 
this regard, it recognised the provision of essential drugs as a component of 
                                                 
46 Anand Grover, ‘Report of the Special Rapporteur on the right of everyone to the 
enjoyment of the highest attainable standard of physical and mental health’ (1 May 2013) 
23rd Session Agenda Item 3 UN Doc A/HRC/23/42 para.3 
47 Alicia Ely Yamin, ‘Not Just a Tragedy: Access to Medications as a Right Under 
International Law’ (2003) 21 (2) Boston University International Law Journal p.336  
48 supra note 25 p.113 
49 WHO Constitution 
50 OHCHR and WHO, ‘The Right to Health’ Fact Sheet No.31 (2008) p.9-10 
51 WHO, ‘Declaration of Alma-Ata’ International Conference on Primary Health Care (6-
12 September 1978) 
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primary health care.52 Since then, various human rights instruments have 
referenced the Alma Ata Declaration. 
Article 12 of the ICESCR53 and general comment No. 14,54which was 
issued by the CESCR on 11 August 2000 offers a detailed normative 
content for the right to health. All health facilities, goods and services must 
be available, accessible, acceptable and of good quality.55 Article 12(2)(d) 
of the ICESCR requires state parties to create “conditions which would 
assure to all medical service and medical attention in the event of 
sickness”.56 General comment No.14, under the scope of this provision, 
specifically refers to access to essential medicines.57 It states that access to 
essential medicines, as defined by the WHO Action Programme on Essential 
Drugs58 is one of the core obligations of the state parties.59 This means that 
it is the minimum essential level of the right to health, which must be 
immediately satisfied by the state.60 Every state is expected to have a 
national list of essential medicines by taking the WHO list of essential 
medicines as a model. It is the country’s responsibility to decide which 
medicines are essential. The CESCR has addressed states’ failures to meet 
their core obligations in concluding observations.61 Additionally, the 
Optional Protocol to the ICESCR62, which entered into force on 5 May 
2013, brings the possibility of individual communication to the CESCR. It 
can serve as another forum where the Committee can contribute to the 
normative content of the right to health. 
                                                 
52 Ibid. 
53 International Covenant on Economic, Social and Cultural Rights (16 December 1966) 
993 U.N.T.S.3 
54 CESCR, ‘General Comment No.14 : The Right to the Highest Attainable Standard of 
Health’ (11 August 2000) 22nd Session E/C/.12/2000/4 
55 Ibid. 
56 ICESCR Art.12(2)(d) 
57 supra note 54 para.17 
58 WHO, ‘Action Programme on Essential Drugs: Collaboration Between NGOs, Ministries 
of Health and WHO in Drug Distribution and Supply’ (1998) WHO/DAP/98.12 
59 supra note 54 para.43 
60 Ibid. 
61 CESCR, ‘Concluding Observations of the Committee on Economic, Social and Cultural 
Rights: Honduras’ (21 May 2001) UN Doc E/C.12/1/Add.57 para.26; see also supra  note 
47 p.337 
62 UN General Assembly, ‘Optional Protocol to the International Covenant on Economic, 
Social and Cultural Rights’ (10 December 2008) A/RES/63/117 
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General comment No.1763 on Article 15(1)(c) of the ICESCR is also very 
important in the sense of reflecting the Committee’s perspective on the issue 
despite not explicitly referring to access to medicines: 
In contrast with human rights, intellectual property rights are generally of a 
temporary nature, and can be revoked, licensed or assigned to someone else. 
While under most intellectual property systems, intellectual property rights, 
with the exception of moral rights, may be allocated, limited in time and 
scope, traded, amended and even forfeited, human rights are timeless 
expressions of fundamental entitlements of the human person.64  
The mandate of the Special Rapporteur is also worth referring to when the 
access to medicines is at stake. The Special Rapporteur is appointed by the 
Human Rights Council to present annual reports, monitor the situation of 
the right to health throughout the world, make country visits to obtain first-
hand information, communicate with states and other concerned parties with 
regard to alleged cases of violations and other issues assigned to him or 
her.65 For example, Paul Hunt who served as the Special Rapporteur from 
2002 to 2008 visited the headquarters of GlaxoSmithKline (GSK) in June 
2008 and reviewed its policies regarding access to medicines.66 He also 
issued the ‘Human Rights Guidelines for Pharmaceutical Companies in 
relation to Access to Medicines’67 among other important reports.68 It 
contains forty-seven detailed guidelines concerning a wide range of topics 
from transparency, management, monitoring and accountability to neglected 
diseases, patents, licensing, pricing and donations. The current Special 
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Rapporteur, Anand Grover, pays special attention to the access problem as 
well since he was appointed in August 2008.69  
2.3 A shortcoming 
 
Although the efforts mentioned above are welcoming, the access problem 
still exists due to a wide range of shortcomings.70 One major problem is that 
the responsibilities of non-state actors are very ambiguous. Obligations are 
mainly placed on states in international law, including international human 
rights and intellectual property law. For example, the WTO is a member-
driven organization, which means that all the decisions are taken by the 
governments. Non-state actors can have a voice only through their 
governments. Similarly, international human rights law is established on the 
idea that human rights are to be claimed against the sovereign power of 
states because the state is the only actor, which can violate human rights. 
Therefore, only states are bound by those international instruments 
previously exemplified. For instance, when the Special Rapporteur Paul 
Hunt issued a report about the operations of GSK71, the company stated that 
“the right to health is an important issue, though not well defined, especially 
as it relates to non-state actors. Therefore, we do not accept the suggestion 
— implicit in the development of this report — that GSK’s programme and 
ongoing commitment is in any way required by international legal norms, 
whether in human rights or other areas”.72  
When the responsibility of non-state actors is put under the spotlight, it is 
mainly rectified within the scope of the state responsibility to ‘protect’ 
human rights. General comment No. 14 paragraph 42 states that “while only 
states are parties to the Covenant and thus ultimately accountable for 
compliance with it, all members of society, including the private business 
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sector, have responsibilities regarding the realization of the right to health. 
State parties should therefore provide an environment which facilitates the 
discharge of these responsibilities”.73 Likewise, paragraph 35 shares the 
same attitude. “States have the obligation to ensure that privatization of the 
health sector does not constitute a threat to the availability, accessibility, 
acceptability and quality of health facilities, goods and services”.74   
At this point, optional business accountability efforts come to mind. 
Voluntary self-regulatory business regimes transpired under the heading of 
corporate social responsibility (CSR).75 These approaches can lack a 
specific reference to human rights. They generally deal with the access 
problem as part of philanthropy; which is commendable when it takes place 
but it is entirely optional and can be discontinued or reduced at any time 
according to the company’s preferences and profit evaluations. As Bilchitz 
puts it, to ensure that individual rights are realised, it would be entirely 
ineffective to rely on the contingencies of social pressure or corporate good 
will.76 
In summary, this chapter presented the background of the access problem by 
way of referring to intellectual property and human rights legal regimes. 
While the TRIPS Agreement has been causing great concern on the ground 
that it ignores the needs, interests and goals of the less developed member 
states77, it still holds certain safeguards that less developed countries can 
benefit through Articles 7, 8 or Article 31, which are reinforced by the Doha 
Declaration and Decision of 30 August 2003.78 In international human rights 
law, access to essential medicines is discussed under the umbrella of right to 
health. ICESCR and general comment No.14 of the CESCR consider the 
access to essential medicines as one of the core obligations of the right to 
health, which requires immediate realisation regardless of whether the state 
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has available resources or not. The access problem has also constituted a 
major part of the mandate of the Special Rapporteur. Lastly, the chapter 
emphasized the fact that both legal regimes are built on the state-centric 
governance mechanism, hence, not focused on the role of non-state actors in 
the access to medicines. This is the stage where the SRSG’s mandate will 
come into play in the following chapter.          
 
 21
3 Corporate Responsibility to 
Respect Human Rights 
3.1 Introduction 
 
“The harms individuals may suffer are not limited to ones where their rights 
are actively violated by corporations: indeed, lack of access to food, water, 
healthcare, and legal representation may severely impact upon the lives of 
individuals”.79  
The image of pharmaceutical companies was damaged dramatically during 
the litigations against the South African and Brazilian governments. When 
the South African government passed the law on compulsory licensing of 
HIV/AIDS medicines in 1997, thirty-nine pharmaceutical companies 
brought a court action against the South African government.80 When the 
Brazilian government started following a similar strategy, the U.S. brought a 
WTO case against Brazil in 2001.81 However, pharmaceutical companies 
had to drop their court action and the U.S. government had to withdraw its 
WTO case against Brazil due to aggressive civil society and media 
counteractions.82 
The SRSG explains the current business and human rights predicament as a 
result of the “governance gaps created by globalisation-between the scope 
and impact of economic forces and actors, and the capacity of the societies 
to manage their adverse consequences”.83 The Framework and the U.N. 
Guiding Principles emerged in response to those governance gaps. 
After presenting the background to the U.N. Guiding Principles, this chapter 
will clarify the limitations of the ‘respect’ human rights notion as used in the 
U.N. Guiding Principles. Subsequently, it will avail itself of the human 
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rights due diligence concept to interpret ‘respect’ in the context of patent-
holding pharmaceutical industry. This will be done by way of referring to 
the right to health framework drawn by the international human rights 
authorities. 
3.2 Background of the Guiding Principles 
 
As the economic globalisation intensified, the U.N. has been focussing 
greatly on business-related human rights violations over the past two 
decades. One initiative was the U.N. Norms on the Responsibilities of 
Transnational Corporations84 (Norms) drafted between 1998 and 2004. 
However, it resulted in a deeply divisive debate between the business 
community and human rights advocacy groups while evoking little support 
from governments.85 After the Sub-Commission on the Promotion and 
Protection of Human Rights submitted the Norms to the Commission on 
Human Rights (replaced by the Human Rights Council in 2006), the 
Commission decided not to endorse them.86 Therefore, in July 2005, the 
then U.N. Secretary-General Kofi Annan appointed John Ruggie as Special 
Representative of the U.N. Secretary-General on the issue of human rights 
and transnational corporations and other business enterprises to undertake a 
new process.87  
Ruggie consulted a wide range of stakeholders88 to have a participatory 
process for reducing the extent of polarisations within the business and 
human rights discussions. In April 2008, he developed the ‘Protect Respect 
Remedy’ Framework, which comprises three core pillars: the state duty to 
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protect against human rights abuses by third parties, including business, the 
corporate responsibility to respect human rights, and the need for more 
effective access to remedies.89 The Framework was unanimously endorsed 
by the U.N. Human Rights Council and widely welcomed by various 
stakeholders; individual governments, business enterprises and associations, 
civil society and workers’ organisations, national human rights institutions 
and investors.90  
After receiving positive widespread reception91, the SRSG produced the 
U.N. Guiding Principles on Business and Human Rights for operationalising 
the Framework and further defining the key duties and responsibilities of 
states and business enterprises with regard to business-related human rights 
abuses.92 This is the final report of the SRSG’s six year mandate between 
2005 and 2011. Similar to the Framework, U.N. Human Rights Council 
endorsed the Guiding Principles unanimously in June 2011. 
3.3 Scope of Respect 
 
Guiding Principle 11 sets the foundational principle of corporate 
responsibility to respect human rights as follows:  
Business enterprises should respect human rights. This means that they 
should avoid infringing on the human rights of others and should address 
adverse human rights impacts with which they are involved.93 
This is the baseline expectation for all companies in all situations.94 The 
SRSG explains it as a responsibility based on “social expectations-as part of 
what is sometimes called a company’s social license to operate”.95  
Ruggie had to follow a pragmatic strategy during his six year mandate to 
reduce the existing polarisations and find a focal point where different 
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stakeholders’ expectations can converge.96 As a result, he avoided 
identifying corporate duties as ‘legally’ mandated or compulsory, preferring 
to identify them simply as ‘responsibilities’ or ‘social duties’ emanating 
from the ‘social license’ businesses need to operate.97  According to Paul 
Hunt, no matter how the relationship between the patent-holder company 
and society is categorised, “the company holds the patent on express and 
implied terms. Society has legitimate expectations of a company holding the 
patent on a life-saving medicine”.98 
The SRSG’s responsibility to respect is a result of inspiration from the 
international human rights law terminology. He adapted the standard human 
rights definition of ‘respect’ into the U.N. Guiding Principles.99 
“Responsibility to respect is defined in terms of the classic human rights 
meaning of respect: non-infringement on the rights of others, and 
addressing harms that do occur”.100  
Respect, as understood in the human rights framework, generally suggests 
minimum standards of non-infringement. States’ positive obligations are 
widely seen to be embedded in the other two terms within the paradigm of 
protect and fulfil.101 However, the SRSG claims that corporate responsibility 
to respect is not necessarily a “mere analogue to a negative duty”102 and 
gives examples to prove that. He acknowledges that the responsibility to 
respect “may entail positive steps - for example, a workplace anti-
discrimination policy might require the company to adopt specific 
recruitment and training programmes”.103 In his 2009 report, he also points 
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out that even the mere fact that companies are required to set up grievance 
mechanisms where none exist and the existence of the concept of human 
rights due diligence, requiring companies  to become aware of, prevent and 
address adverse human rights impacts are themselves positive acts.104 
However, this kind of exemplification limited only to a few examples 
cannot lead one to a comprehensive answer regarding the boundaries of this 
responsibility in the access to medicines. 
Corporate responsibility to respect applies to every business enterprise 
regardless of their size, sector, operational context, ownership and structure. 
However, the scale and complexity of the means through which enterprises 
meet that responsibility may change according to those factors.105 Ruggie 
states that “the principles are principles.  They are not a toolkit.  You do not 
take it off the shelf and plug it in, and get an answer.  Issues of context, 
issues of industry sector, matter...”106  
What respect signifies will vary considerably depending on where the 
pharmaceutical company operates, whether it owns any patent rights or how 
severe its human rights impact is, among others. In other words, the U.N. 
Guiding Principles’ approach is not a ‘one size fits all’. It applies to 192 
United Nations member states, 80,000 transnational enterprises, 10 times as 
many subsidiaries and countless millions of national firms, most of which 
are small and medium sized enterprises.107    
The basic requirement, which is common for every industry, is to comply 
with the national law and international standards in case the former is either 
absent or not in line with the latter.108 What is more is the concept of human 
rights due diligence as a context-dependent tool of operationalisation.  
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3.3.1 Human rights due diligence as an 
implementing tool 
Human rights due diligence is the necessary tool for any enterprise to ‘know 
and show’ that it is respecting human rights in practice.109 “It is through the 
human rights due diligence that an enterprise identifies the information it 
needs in order to understand its specific human rights risks at any specific 
point in time and in any specific operating context, as well as the actions it 
needs to take to prevent and mitigate them”.110 A company’s human rights 
due diligence process must include all the elements set out in the Guiding 
Principle 17, i.e. assessing actual and potential human rights impacts, 
integrating and acting upon the findings, tracking responses, and 
communicating how impacts are addressed.111  
Human rights due diligence is not measured by any absolute standard, but it 
depends on the relative facts of the specific case.112 “Enterprises of different 
sizes, in different industries, with different corporate structures and in 
different operating circumstances will need to tailor their processes to meet 
those needs”113  
The Framework defines the scope of responsibility in terms of actual and 
potential adverse human rights impacts arising from a business enterprise’s 
own activities and from the relationships with third parties associated with 
those activities.114 The company can be involved in those adverse impacts in 
three ways: it can cause the impact, contribute impact through its own 
activities or the impact can be directly linked to its operations, products or 
services by its business relationships.115    
“The Committee on Economic, Social and Cultural Rights and others have 
developed a framework for analysing or “unpacking” the right to health with 
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a view to making it easier to understand and apply”.116 This thesis will avail 
itself of this framework to show the actual and potential adverse human 
rights impacts of patent-holding pharmaceutical companies. 
3.3.1.1 The right to health framework 
 
Interrelated and essential elements of the right to health are taken as a 
guideline: All health services, goods and facilities, including medicines, 
should be made available, accessible, acceptable and of good quality.117  
(a) Availability 
Medicines must be available ‘in sufficient quantities in the countries where 
they are needed’.118  Availability of medicines is specifically important in 
the context of neglected tropical diseases. “Neglected tropical diseases 
(NTDs) are a group of infectious diseases that disproportionately affect the 
world’s poorest and most vulnerable populations. It is estimated that more 
than one billion people are affected by NTDs, including roughly 800 million 
children”.119 Those diseases traditionally receive very little attention 
because the potential customer cannot afford the excessive drug prices.120  
It is worth highlighting that this deficiency is in fact a result of current 
patent regimes, which are driven by commercial concerns of developed 
countries rather than being a result of actions or omissions of 
pharmaceutical companies directly. Current pharmaceutical patent regimes 
channel research and development towards drugs, which could generate 
revenue for the company, creating a lack of investment for NTDs since 
those diseases do not present a lucrative market.121 Therefore, for the 
purposes of this thesis, the lack of investment in NTDs is not considered as 
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an adverse impact of patent-holding pharmaceutical companies directly but 
instead as a deficiency of the overall patent regimes. 
(b) Accessibility 
Accessibility is the other essential element in the right to health. It has four 
overlapping dimensions, i.e. non-discrimination, physical accessibility, 
economic accessibility - affordability - and information accessibility.122 
Physical accessibility means that medicines must be accessible to all parts of 
a country, in both rural and urban areas.123 To fully ensure accessibility, 
medicines must be affordable to all, including those living in poverty.124 
Finally, accessibility of information and transparency regarding the 
medicine’s safety or side effects should be ensured as well.125 
Patent rights inherently increase the cost of drugs. The raison d’être of 
patents is to encourage more innovation by way of providing monopoly in 
the market and financial incentive to the original owner. This carries special 
importance for pharmaceutical companies because “pharmaceutical industry 
is a science industry for which innovation is the fundamental source of 
competitiveness”.126 As a result, the price of a drug includes not only the 
cost of making it but also R&D and marketing costs.127 This makes the 
drugs unaffordable to segments of the population who could have paid for 
the drugs had they been sold at their marginal cost of production.128 
Another concern is the patent-holding companies’ efforts to curtail local 
pharmaceutical production. If this was not prevented, drug prices can 
become more affordable due to increasing generic competition in the 
country concerned. The pharmaceutical industry actively participates in 
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persuasive lobbying activities. The practise shows that countries who want 
to use TRIPS flexibilities such as compulsory licensing or parallel importing 
are either prevented through TRIPS-plus agreements or are threatened with 
trade sanctions as well as corporate litigations in bilateral arena as 
exemplified previously in cases of South Africa and Brazil.129  
TRIPS-plus agreements refer to bilateral or regional trade agreements, 
mostly free trade agreements and bilateral investment treaties, in which 
mainly developed countries sign with the developing world. Those 
agreements, 1) impose more stringent intellectual property protection 
standards than TRIPS require such as extending the term of patent 
protection over twenty years, limiting compulsory licensing, parallel import 
possibilities or expanding the patentable subject matters excessively 2) 
oblige developing countries to implement TRIPS before the end of 
transition periods130 that TRIPS brings or 3) require developing countries to 
conform other multilateral intellectual property agreements.131 The current 
European Union - India Free Trade Agreement that has been under 
negotiation since 2007 is one example. It aims to curtail Indian generic 
medicine production, which has become to be known as the pharmacy of the 
developing world for years. 
Such agreements undermine the generic pharmaceutical production by 
“strengthening the position of originator-patent holder pharmaceutical 
enterprises on national markets”.132 Generic pharmaceutical production is 
one of the most effective methods to cut down the price of medicine and 
overcome access problems in the long term. Therefore, patent-holding 
pharmaceutical companies are expected to respect the TRIPS Agreement 
flexibilities and Doha Declaration and Decision of 30 August 2003. 
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Responsibility to respect includes not entering into agreements, which 
destroys the TRIPS flexibilities.133 
Companies’ patent applications for insignificant changes to existing drugs 
pose a big concern as well in relation to affordability. Patent-holding 
pharmaceutical companies developed this ever-greening strategy in order to 
extend their monopoly in the market. As a result, this delays the generic 
competition in the country and medicines are sold at higher prices over a 
longer period. Studies show that research and development is a relatively 
small part of the budgets of big drug companies; dwarfed by their vast 
expenditures on marketing and administration, and even smaller than 
profits.134 Furthermore, it can be argued that the pharmaceutical industry is 
not especially innovative. The great majority of ‘new’ drugs are not new at 
all but merely variations of older drugs already on the market. 135 “While 
globally, the level of patent protection has increased over the past twenty 
years, the rate of pharmaceutical innovation has fallen, with an increasing 
number of ‘me-too drugs’ of little or no therapeutic gain”.136 However, if the 
aim is to incentivise only the genuine research, then companies are expected 
to be more mindful of economic accessibility and not resort to ever-greening 
practices. 
In addition to economic accessibility, accessibility of information, which 
means the right to seek, receive and impart information and ideas 
concerning health issues,137 is also an essential part of the right to health. It 
has particular importance when transparency is threatened during TRIPS-
plus negotiations. Parties in those agreements mostly ignore the public’s 
right to information and participation in the conduct of public affairs, which 
are both very critical for the full realisation of right to health.138 For 
instance, the European Union - India Free Trade Agreement or rather the 
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Trans-Pacific Partnership Agreement139 processes have been conducted 
secretly. The little that the public knows is through leaked information. 
Another common concern regarding the accessibility of information is the 
test data exclusivity practices of patent-holding pharmaceutical companies. 
Before the marketing of a pharmaceutical product, companies are legally 
required in most countries to provide data regarding the safety, quality and 
efficacy of new medicines, validated through medically and ethically valid 
clinical trials.140 However, the practise shows that trial data are not made 
public by companies on grounds of protecting their commercial information. 
In some situations, even if they do disclose information, they tend to show 
only positive results, which is misleading and detrimental to patients.141 
(c) Acceptability and Quality 
Acceptability and quality are other essential elements of the right to health. 
While acceptability means that medicines and associated processes such as 
clinical trials must be respectful of medical ethics, culturally appropriate, 
sensitive to gender as well as life cycle issues, the quality element refers to 
the responsibility to ensure that their medicines are of good quality, safe and 
efficacious. An important point in this regard is the confusion between poor-
quality drugs and generic drugs. Some countries even take unilateral actions 
against legitimate generic medicines as being counterfeit due to this 
misinterpretation.142 This type of policy deviates considerably the promotion 
of local production of medicines and public health efforts. 
3.4 Conclusion 
 
In summary, this chapter introduced the reader to the background of the 
U.N. Guiding Principles and showed what motives it had behind its 
existence. The concept of human rights due diligence provided the 
necessary guidance and flexibility to envision the adverse human rights 
impacts of patent-holding pharmaceutical companies. In doing so, the 
                                                 
139 For the negotiator countries <http://tppinfo.org/> accessed on 26 May 2014  
140 supra note 46 para.63 
141 Ibid. 
142 Ibid para.66 
 32
chapter took the guidance of the right to health framework. Those adverse 
impacts can vary from the lack of investment in research and development 
of NTDs to companies’ strong lobbying activities to maintain high drug 
prices and ever-greening practices. The aim was not to make an exhaustive 
list of impacts one by one, but instead to give a glimpse of how 
pharmaceutical patents influence the access to medicines. This was specially 
necessitated by the fact that the following chapter will refer to those adverse 
impacts while challenging the boundaries of corporate responsibility to 
respect.  
 33
4 More than respect? 
4.1 Introduction 
 
When adverse impacts of pharmaceutical companies are investigated, it 
appears that some of them necessitate certain positive acts on behalf of 
companies. The question is whether those acts have any standing in the U.N. 
Guiding Principles. 
In the access problem, for the U.N. Guiding Principles to offer any efficacy, 
they need to be interpreted in a way covering positive measures as well. 
Companies must be required to take certain initiative and act upon their 
adverse impacts. Lack of access to essential medicines differs from other 
areas of business related human rights violations such as the environmental 
harms caused by large-scale oil extraction, racial or religious discrimination 
in the workplace, right to privacy in the information technology domain or 
respecting patients’ right to health in clinics.  
According to the SRSG, “companies may undertake additional 
commitments voluntarily or as a matter of philanthropy. Moreover, some 
have developed new business opportunities by offering goods and services 
more closely aligned with basic needs, as in bottom-of-the-pyramid 
strategies and other types of inclusive business models. These are worthy 
endeavours that may contribute to the enjoyment of human rights. But what 
it is desirable for companies to do should not be confused with what is 
required of them”.143 At this point, the question arises as to which acts are 
within the scope of ‘respect’, and which ones lie outside and fall into the 
domain of desired but not required acts.  
The aim of this chapter is to challenge the boundaries set for corporate 
responsibility to respect and prove that it is indeed possible to expand the 
interpretation in certain cases. For this purpose, the chapter will initially 
present the case of price reductions in life-saving medicines where the 
narrow understanding of corporate responsibility to respect is insufficient. 
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In doing so, it will avail itself of current practices of patent-holding 
pharmaceutical companies such as participation in multi-stakeholder 
initiatives and voluntary licensing agreements. Afterwards, the thesis 
attempts to justify that there is in fact opportunity for broader interpretation 
by referring to both the concept of human rights due diligence and other 
supportive arguments. 
4.2 Cases 
4.2.1 Price reductions in life-saving medicines 
When the U.N. Declaration of Commitment on HIV/AIDS144 was endorsed 
by the General Assembly in 2001, it recognised that pharmaceutical 
companies are central to reducing the cost of HIV/AIDS medicines and 
ensuring the availability thereof.145 It provides that: 
“The cost, availability and affordability of drugs and related technology are 
significant factors to be reviewed and addressed in all aspects and that there 
is a need to reduce the cost of these drugs and technologies in close 
collaboration with the private sector and pharmaceutical companies”.146 
Companies have a wide range of options available to them to reduce the 
prices of life-saving drugs, e.g. offering differential pricing, participating in 
multi-stakeholder initiatives, or engaging in voluntary licensing agreements. 
For example, Abbott and Novartis focus on delivering low-cost medicines 
through differential pricing strategies.147 However, this chapter will only 
focus on the participation in multi-stakeholder initiatives and voluntary 
licensing agreements, which offers a long-term solution for the ‘steady 
supply of essential medicines’.148 
 
                                                 
144 UN General Assembly, ‘Declaration of Commitment on HIV/AIDS’ (2 August 2001) 
26th Session Agenda Item 8 UN Doc A/RES/S-26/2 
145 supra note 76 p.212 
146 supra note 144 
147 Access to Medicine Foundation, ‘Access to Medicine Index’ (November 2012) p.62 
148 UNCTAD, ‘Local Production of Pharmaceuticals and Related Technology Transfer in 
Developing Countries: A Series of Case Studies by the UNCTAD Secretariat’ (2011) 
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4.2.1.1 Participation in multi-stakeholder initiatives 
 
The Institute for Human Rights and Business (IHRB) observes that as ‘some 
problems go beyond national borders’, developing governance mechanisms 
that are effective beyond borders ‘may require non-State actors’ 
participation, with corresponding delineation of rights and 
responsibilities’.149  
Multi-stakeholder initiatives have been offering a promising increase in 
access to HIV/AIDS medicines by pulling down the drug prices. For 
example, “in July 2013, UNAIDS joined with WHO, the US President’s 
Emergency Plan for AIDS Relief (PEPFAR), the Global Fund to Fight 
AIDS, Tuberculosis and Malaria and other partners to launch the Treatment 
2015 initiative, which aims to ensure that the world reaches its 2015 HIV 
treatment target as a critical stepping-stone towards universal access 
treatment”150. The goal is to provide ARV therapy to 15 million people by 
2015.    
Initiatives of the Global Fund to Fight AIDS, Tuberculosis and Malaria also 
have been offering very successful examples since 2002. For instance, its 
Affordable Medicines Facility for Malaria allows people to buy life-saving 
malaria treatment for less than one U.S. dollar. Comparable malaria 
medicines outside the program cost up to ten to twenty times as much.151 
Multi-stakeholder initiatives play a major role in research and development 
for NTDs as well. For example, DNDi is a product development partnership 
founded in July 2003, which includes numerous partners from the 
pharmaceutical industry such as AbbVie (formerly Abbott), Astra Zeneca, 
Bristol Myers Squibb, CIPLA, GNF Novartis, Merck & Co., Pfizer Limited 
and many more.152 In 2007, DNDi brought out its first product: a simple, 
affordable and effective anti-malarial fixed-dose combination, combining 
                                                 
149 supra note 14 p.223; see also supra note 101 p.8 
150 supra note 1 p.46 
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two anti-malarials in a single pill. Since then, it has given rise to a total of 
four new products onto the market, a second new treatment for malaria and 
treatments for Visceral Leishmaniasis and Human African Trypanosomiasis 
(HAT)/ sleeping sickness.153  
In Paul Hunt’s words, while the company cannot be expected to make an 
overall loss, it can sometimes be expected to operate, with respect to some 
of its activities, on a not-for-profit basis.154 
4.2.1.2 Voluntary licensing agreements as a tool to 
encourage local production 
There is a new focus on local production as a means of contributing to the 
overall goals of promoting innovation, building capacity and improving 
access.155 
Firstly, local production can increase price-based competition in the market, 
contributing and ensuring lower drug prices and greater affordability.156 
Secondly, local production can in the future fill an important gap for 
developing country needs in case Indian generic companies continue to shift 
their focus to developed country markets and needs. With improved 
production and R&D capacities, Indian firms have started targeting more 
affluent markets and their specific disease patterns.157 Mergers and 
acquisitions of large Indian companies with global pharmaceutical 
companies and other political economy factors such as free trade agreements 
threaten the future of generic drug manufacturing.158 Thirdly, generic 
pharmaceutical companies have extensive distribution networks. Most local 
companies are adept at using context-relevant strengths for distributing their 
products and in creating newer modes of distribution for their medicinal 
products.159  
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Non-exclusive voluntary licenses have the most potential to encourage 
generic drug competition, especially when they are accompanied with the 
necessary technology transfer. However, only a few companies make use of 
them. Gilead, GlaxoSmithKline and Merck & Co. are the most advanced, 
with Gilead openly recognising the value of engagement with the generic 
industry’s capacity to produce high volumes of low-cost and high-quality 
medicines.160 At this point, the absorptive capacity, availability of human 
skills to engage in production, management, marketing and relevant 
scientific and physical infrastructure should be taken into consideration 
when transferring technology.161 
4.2.1.2.1 Medicines Patent Pool 
 
A voluntary licensing initiative is the Medicines Patent Pool (MPP), which 
aims to reduce the prices of HIV medicines and facilitate the development 
of better-adapted HIV medicines in developing countries.162  
When a company aims to produce generic drugs, it can acquire a license 
from the MPP in return for a certain amount of royalty. The notion behind 
the MPP mechanism is that it would reduce drug prices by encouraging the 
generic competition and alleviate the access problem considerably. A Pool 
would also make the development of more adapted medicines easier. For 
instance, a company wanting to combine drugs in a new fixed-dose 
combination - when several drugs are integrated into a single pill - will only 
have to deal with the patent pool – and not all the patent-holding 
companies.163  
The method that the MPP uses is voluntary licensing, i.e. voluntary 
licensing of key HIV medicine patents. Fixed-dosed combination drugs are 
what the MPP promotes for local production. It proved to simplify treatment 
for people living with HIV and facilitate scaled-up treatment in developing 
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countries.164  Since 2010, a number of companies with relevant HIV drugs 
in their portfolios have entered into formal negotiations with the MPP.165 
4.3 Justification for broader interpretation 
4.3.1 Analysis within the scope of human rights 
due diligence 
The human rights due diligence concept, which is tightly embedded in the 
responsibility to respect, must be approached according to certain steps. 
When a company’s operational area is resource-poor as well as prone to a 
certain disease, e.g. hepatitis C in India, then this operational area exhibits 
particular risks for which the company should consider when assessing its 
actual and potential adverse impacts, act upon these risks, track whether the 
response is effective and communicate externally how those impacts are 
addressed.166 Throughout these defined steps, the company is highly 
expected to engage with affected stakeholders. 
Guiding Principle 19 states that: 
     In order to prevent and mitigate adverse human rights impacts, business 
enterprises should integrate the findings from their impact assessments 
across relevant internal functions and processes, and take appropriate 
action.167  
Appropriate action will vary depending on the company’s involvement in 
the adverse impact. When a pharmaceutical company offers excessive drug 
prices to a resource-poor country, then it can be involved in the adverse 
impact by different ways depending on the specifics of each case. At this 
point, Guiding Principle 19 provides the appropriate actions expected from 
companies according to degree of their involvement: when the company 
causes or may cause the adverse impact, it then should take the necessary 
steps to cease or prevent it. When the company contributes or may 
contribute to it, it should similarly take the necessary steps to cease or 
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prevent its contribution and use its leverage168 to mitigate any remaining 
impact. Lastly, in more complex situations, even though the company has 
not contributed to the adverse impact, it can still be expected to act upon it 
when the impact is linked to its operations, products or services by its 
business relationship with another entity.169 This entity can be business, 
governmental or non-governmental.170  
The leverage over the entity plays a crucial role when a business 
relationship is involved in the situation. If a company has leverage, it then 
should exercise it. Even when the company does not have it, it is still 
expected to find a way such as offering capacity-building or collaborating 
with other actors to increase the leverage.171 Where the company lacks the 
leverage and is unable to increase it, it then should end its relationship with 
the entity. However, the SRSG clearly suggest that ending the relationship is 
an option only when the company is unable to increase its leverage. 
Therefore, the notion of leverage in fact outweigh the disengagement 
option.172 This provision imposes a responsibility to act on behalf of the 
company. It can be claimed that this requirement clearly goes beyond the 
traditional meaning of ‘respect’ in the human rights regime. In a way, it 
subtly embeds a ‘protect’ nature in corporate responsibility to respect. This 
represents the SRSG’s pragmatic strategy to achieve the convergence of 
stakeholder expectations.173    
Patent-holding multinational pharmaceutical companies are the key players 
in global health policies due to their financial and political powers, as 
previously explained. This thesis has advocated certain corporate actions to 
reduce the prices of essential medicines by way of participating in multi-
stakeholder initiatives and engaging in voluntary licensing agreements 
accompanied by transfer of technology. Within the light of Guiding 
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Principle 19, the company is expected to incentivise the entity to improve its 
right to health performance in terms of future business, reputational 
advantage or transfer of knowledge and technology.174 Business associations 
and multi-stakeholder initiatives can be effective as well in increasing the 
leverage.175 Therefore, this thesis claims that corporate actions that this 
thesis has advocated can be justified as appropriate actions under Guiding 
Principle 19, which attaches a significant importance to the concept of 
leverage. Indeed, the strong emphasis on the stakeholder involvement 
throughout the human rights due diligence process supports this claim as 
well. 
4.3.2 Supportive Arguments 
“An examination of human rights responsibilities beyond the duty to respect 
is critically important because the pharmaceutical sector has highly 
distinctive functions directly impacting upon the life, health and prosperity 
of countless individuals and communities”.176 
Firstly, “why are policies and processes required as in the Guiding Principle 
15 if this is just a question of avoiding harm?”  The OHCHR explicitly 
acknowledges that “respecting human rights is not a passive responsibility: 
it requires action on the part of businesses”177 The SRSG builds the 
corporate responsibility to respect on the concept of “social expectations-as 
part of what is sometimes called a company’s social license to operate”.178  
This social expectation naturally varies depending on the circumstances.  
By limiting the scope of corporate responsibility only to respect and 
asserting that this responsibility is sourced in societal expectations, Guiding 
Principles would actually be claiming that our societal expectations of 
pharmaceutical companies do not extent to a responsibility to help render 
such life-saving medicines affordable to those who need them.179 
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“The agreement between society and patent holder includes a responsibility 
on the patent holder to take these steps, expeditiously and effectively, by 
way of deliberate, concrete and targeted measures...Of course, the success of 
the patent holder’s actions will sometimes depend upon states, donors and 
others in the pharmaceutical sector fulfilling their responsibilities. 
Nonetheless, the patent holder has a right-to-health responsibility to do what 
it can”.180  
Secondly, the IHRB suggested that the activities of certain industries such 
as companies who provide healthcare facilities, food distribution, water 
provisions, and power generation or telecommunications are closely tied 
with the fulfilment and realisation of specific rights. Therefore, these 
companies should have responsibilities beyond respect.181 The IHRB 
highlighted that this must be the case especially in circumstances where the 
state is unable to meet its human rights obligations.182 However, the SRSG 
objected to this idea on the ground that this proposition would “encourage 
endless strategic gaming by states and companies alike about who was 
responsible for what in particular situations”.183 
The SRSG often refers back to the Norms in claiming that the 
responsibilities of companies should not reflect the state obligations: 
“Corporations are not democratic public interest institutions and that making 
them, in effect, co-equal duty bearers for the broad spectrum of human 
rights- and for “the obligation to promote, secure the fulfilment of, respect, 
ensure respect and protect” those rights, as the General Obligations of the 
Norms put it-may undermine efforts to build indigenous social capacity and 
to make Governments more responsible to their own citizenry”.184  
It must be clarified that this thesis is aware of the sensitivity of calling for 
responsibilities beyond respect. It does not claim that further responsibilities 
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should be assigned in a way, “which risks detracting attention away from 
state obligations, making it easier for governments to shirk their own 
obligations”.185 
This thesis does acknowledge though, the overall success can be achieved 
by states and companies together. For example, regarding the physical 
accessibility of drugs, many factors such as local infrastructure or 
distribution capacities depend on the state.186  Another example is the 
expectation that companies should waive test data exclusivity or refrain 
from applying for patents ‘for insignificant or trivial modifications of 
existing medicines’ at low and middle- income countries.187 However, this 
is more likely to happen when states disallow data exclusivity and patents 
on trivial modifications of existing medicines in their national laws188 such 
as India. Indian Supreme Court rejected to uphold the patent on Gleevec, the 
cancer drug developed by Novartis, on the ground that the patent application 
could not satisfy the strict novelty requirement brought by the Indian patent 
law.189 
The SRSG also states that these additional responsibilities ‘undermine 
corporate autonomy, risk taking and entrepreneurship’.190 Philip Alston 
asks, “if the private sphere is distinguished from the public sphere by virtue 
of its emphasis on autonomy, risk-taking, entrepreneurship, and the rational 
pursuit of self-interest, what are the consequences of saddling it with all of 
the constraints, restrictions and even positive obligations which apply to 
government?”191 Bilchitz’s argument is worth highlighting at this point:  
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“Imposition of some positive obligations upon corporations would not 
saddle them with all of the obligations that apply to government”.192 
Nevertheless, he accepts that at a certain point, the company may claim that 
it has no reason to continue to invest in research and development if it is 
faced with overly onerous positive obligations, which causes a 
diminishment of profits. However, this does not provide a case against his 
argument. Instead, what it shows is that a balance is necessary if one wishes 
to gain both the traditional benefits of the market-place and additional social 
advantages for the realisation of human rights.193 He refers to ‘push 
programmes’ through which government may help subsidise such research 
and ‘pull programmes’ which reward developers for producing a product 
with strong social benefits.194 
“What is needed is thus a movement away from the traditional assumption 
embedded in the Ruggie framework that only governments are responsible 
for the realisation of rights and the recognition that, in many cases, it will be 
necessary to involve wider social actors in this task”.195  
Another important point is the renouncement of the phrase ‘doing no harm’ 
in the U.N. Guiding Principles. The Framework states that the responsibility 
to respect means not to infringe on the rights of others. Put simply: to do no 
harm.196 However, when one delves in more in-depth into the U.N. Guiding 
Principles, it appears that the phrase of ‘doing no harm’ which is used in the 
Framework has disappeared.197 It instead explains the responsibility to 
respect as to avoid infringing and to address human rights impacts with 
which they are involved.198 According to Mares, this shift is deliberately 
done to prevent the misinterpretation of the phrase ‘doing no harm’ as a 
purely negative responsibility to avoid or to refrain in order not to harm.199 
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This change of terminology might alone not be a strong indicator. However, 
it certainly opens the doors to interpret the Pillar II in a broader manner.  
Finally, when analysing typologies, Shue’s words should be recalled:  
“Now, almost everyone involved in these discussions realizes that 
typologies are not the point. Typologies are at best abstract instruments for 
temporarily fending off the complexities of concrete reality that threaten to 
overwhelm our circuits. Be they dichotomous or trichotomous, typologies 
are ladders to be climbed and left behind, not monuments to be caressed or 
polished”.200  
In this regard, the label of responsibility to respect is not the point. 
Therefore, the interpretation of the Pillar II should not be strictly limited 
within the typology.  
4.4 Conclusion 
 
This chapter challenged the boundaries set by corporate responsibility to 
respect with the help of specific examples. For the Pillar II to be effective, 
the sphere of required acts should be expanded in favour of access to 
medicines. When the question arises as to whether the proposed solutions 
such as multi-stakeholder initiatives or promoting the local production 
through licenses bring a permanent solution to the access problem, the 
answer would be negative. The cancellation of the Global Fund Round II201 
serves a good example in this regard. “With the Global Fund, unprecedented 
levels of donor money were channelled towards saving lives. But ten years 
on, global health is suffering from a sudden shortfall in funding, as donor 
countries leave the Fund in dire financial straits”.202 Therefore, those efforts 
offer practical solutions for particular situations. However, it is very 
difficult to claim that they bring an end to the clash of patent rights and 
human right to health.  
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5 Concluding Remarks 
 
 
The research question that this thesis sought to answer was the meaning of 
corporate responsibility to respect human rights with regard to patent-
holding pharmaceutical companies, more specifically, whether the corporate 
responsibility to respect as framed by the U.N. Guiding Principles is 
comprehensive enough to meet the right to health requirements in the access 
to medicines or not. In answering the research question, the thesis suggested 
that corporate responsibility to respect has the potential to enable greater 
access to essential medicines and allows for broader interpretation of 
respect, requiring positive actions from pharmaceutical companies in certain 
situations, e.g. price reductions in life-saving medicines.  
Different disciplines, in particular, intellectual property and human rights 
legal regimes have been searching for a stable and feasible solution to the 
access problem. It is often claimed that a balance needs to be achieved 
between pharmaceutical patents and the right to health.203 This thesis has 
approached the problem by putting forward the corporate responsibility to 
respect, which can serve as a means to finding a balance.  
Human rights due diligence is the prime element in operationalising the 
corporate responsibility to respect. It clearly requires companies to assess 
their actual and potential adverse human rights impacts. In this regard, the 
thesis has indicated how pharmaceutical companies adversely influence the 
essential elements of right to health through their patent rights. In close 
connection to these impacts, the thesis has advocated that the corporate 
responsibility to respect should not be confined to the traditional meaning of 
respect as framed in international human rights law. The example of price 
reductions in life-saving medicines is given to suggest that in certain 
situations, corporate responsibility to respect requires companies to take 
positive actions such as participating in multi-stakeholder initiatives or 
engaging in voluntary licensing agreements. This claim has been reinforced 
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by the concept of human rights due diligence which requires companies to 
take appropriate actions to prevent and mitigate their adverse human rights 
impacts. This requirement is valid even in the situations where the company 
is involved in the adverse impact solely due to its business relationship with 
another entity. The company is expected to use every means available to 
prevent and mitigate adverse impacts such as by exercising leverage over 
the entity as well as increasing leverage in cases where it lacks. The thesis 
invoked the notion of social expectation, which lies behind the very 
existence of corporate responsibility to respect as well. Company’s social 
license to operate necessitates the responsibility to act in certain situations, 
e.g. price reductions in life-saving medicines through different corporate 
actions. At the same time, the thesis also highlighted that calling for 
expansion in the domain of non-state actors’ responsibilities should not be 
understood as deviating attention away from state obligations.204 Overall 
success can only be achieved by involvement of both states and companies 
in the process. 
Consequently, it must be made clear that this thesis does not claim that 
imposing further responsibilities on patent-holding pharmaceutical 
companies will put an end to the access problem. However, it will 
contribute to an improvement in the overall process. The SRSG has already 
achieved a compelling task by simplifying the responsibilities of different 
actors, which was previously a complicated area and helped outline future 
debates. The field of business and human rights will follow a clearer path as 
the implementation of the U.N. Guiding Principles proceeds and 
underdeveloped areas are clarified. Indeed, the SRSG explained further 
expectations by stating that the Council endorsement of the U.N. Guiding 
Principles will “mark the end of the beginning: by establishing a common 
global platform for action, on which cumulative progress can be built, step-
by-step, without foreclosing any other promising longer-term 
developments”.205  
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